PMID- 18828016
OWN - NLM
STAT- MEDLINE
DCOM- 20090401
LR  - 20181113
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 58
IP  - 5
DP  - 2009 May
TI  - Effect of invariant chain on major histocompatibility complex class I molecule 
      expression and stability on human breast tumor cell lines.
PG  - 729-36
LID - 10.1007/s00262-008-0595-1 [doi]
AB  - Invariant chain (Ii) binds to the human leukocyte antigen (HLA) class II molecule 
      and assists it in the process of peptide acquisition. In addition, Ii binds to 
      the HLA class I molecule, although there has been little study of its effects on 
      the HLA class I molecule. In addition to its normal expression on 
      antigen-presenting cells, Ii expression is up regulated in a variety of tumors. 
      By flow cytometric analysis, we found that expression of Ii resulted in an 
      increase in the number of cell surface HLA class I molecules and in the 
      proportion of unstable HLA class I molecules at the surface of breast tumor cell 
      lines. These data suggest that the expression of Ii by tumor cells may 
      quantitatively and qualitatively alter the presentation of antigens on those 
      cells.
FAU - Lin, Xuede
AU  - Lin X
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of 
      Nebraska Medical Center, Omaha, NE, USA.
FAU - Wang, Xiaojian
AU  - Wang X
FAU - Capek, Haley L
AU  - Capek HL
FAU - Simone, Laura C
AU  - Simone LC
FAU - Tuli, Amit
AU  - Tuli A
FAU - Morris, Chantey R
AU  - Morris CR
FAU - Reber, Adrian J
AU  - Reber AJ
FAU - Solheim, Joyce C
AU  - Solheim JC
LA  - eng
GR  - T32 CA009476-18/CA/NCI NIH HHS/United States
GR  - F32 AI055152/AI/NIAID NIH HHS/United States
GR  - T32 CA 009476/CA/NCI NIH HHS/United States
GR  - T32 CA009476-19A1/CA/NCI NIH HHS/United States
GR  - R01 GM057428-07/GM/NIGMS NIH HHS/United States
GR  - F32 AI 055152/AI/NIAID NIH HHS/United States
GR  - R01 GM057428/GM/NIGMS NIH HHS/United States
GR  - P30 CA 036727/CA/NCI NIH HHS/United States
GR  - R01 GM057428-08/GM/NIGMS NIH HHS/United States
GR  - R01 GM 057428/GM/NIGMS NIH HHS/United States
GR  - R01 GM057428-09/GM/NIGMS NIH HHS/United States
GR  - P30 CA036727/CA/NCI NIH HHS/United States
GR  - R01 GM057428-06A2/GM/NIGMS NIH HHS/United States
GR  - T32 CA009476/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20081001
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Peptide Fragments)
RN  - 0 (invariant chain)
SB  - IM
MH  - Adenocarcinoma/immunology/pathology
MH  - *Antigen Presentation
MH  - Antigens, Differentiation, B-Lymphocyte/*immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Breast Neoplasms/genetics/*immunology/pathology
MH  - Carcinoma, Hepatocellular/immunology/pathology
MH  - Cell Line, Tumor/immunology
MH  - Female
MH  - Flow Cytometry
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, MHC Class I
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Histocompatibility Antigens Class II/*immunology
MH  - Humans
MH  - Liver Neoplasms/immunology/pathology/secondary
MH  - Male
MH  - Pancreatic Neoplasms/immunology/pathology
MH  - Peptide Fragments/immunology
MH  - Prostatic Neoplasms/immunology/pathology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Temperature
PMC - PMC2703440
MID - NIHMS70756
EDAT- 2008/10/02 09:00
MHDA- 2009/04/02 09:00
PMCR- 2008/10/01
CRDT- 2008/10/02 09:00
PHST- 2007/12/26 00:00 [received]
PHST- 2008/09/09 00:00 [accepted]
PHST- 2008/10/02 09:00 [pubmed]
PHST- 2009/04/02 09:00 [medline]
PHST- 2008/10/02 09:00 [entrez]
PHST- 2008/10/01 00:00 [pmc-release]
AID - 595 [pii]
AID - 10.1007/s00262-008-0595-1 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2009 May;58(5):729-36. doi: 10.1007/s00262-008-0595-1. 
      Epub 2008 Oct 1.